Prosecution Insights
Prosecution Insights
Tech Center 3700 • Art Units: 1612 1615 1625 1626 1743 3785
This examiner grants 72% of resolved cases
Melissa S. Mercier, an examiner in Tech Center 3700 and Art Unit 1612, has 1212 resolved cases. The allowance rate is 72.1 percent, and the interview lift is 5.8 percent. This 5.8 percent lift shows a modest benefit from interviews compared to the 72.1 percent baseline. The 72.1 percent allowance rate is a well-established metric across the 1212 resolved cases, indicating a generally favorable environment.
The median time to allowance is 1036 days. With 1212 resolved cases, the 72.1 percent allowance rate is a reliable figure for practitioners. Applicants can expect a 1036 day prosecution period. The 5.8 percent interview lift is a helpful tool for applicants in Art Unit 1612. The 1036 day pendency and 72.1 percent allowance rate provide a clear roadmap for prosecution. Counsel should use the 5.8 percent lift to resolve any minor issues that arise during the process.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18498117 | DEODORANT COMPOSITIONS | Non-Final OA | The Procter & Gamble Company |
| 18317625 | MULTI-PARTICULATE PHARMACEUTICAL COMPOSITION OF QUETIAPINE | Final Rejection | Sun Pharmaceutical Industries Limited |
| 18939379 | SALBUTAMOL DELIVERY COMPOSITIONS, DEVICES AND METHODS | Non-Final OA | HONEYWELL INTERNATIONAL INC. |
| 18437509 | COMPOSITIONS AND DEVICES INCORPORATING WATER-INSOLUBLE THERAPEUTIC AGENTS AND METHODS OF THE USE THEREOF | Non-Final OA | Cook Medical Technologies LLC |
| 18563327 | HARD-SHELL CAPSULE WITH INFLUX PREVENTION OF GASTRIC FLUIDS | Non-Final OA | Evonik Operations GmbH |
| 18898086 | COMPOSITIONS AND METHODS FOR TREATING HAIR | Non-Final OA | L'Oreal |
| 18951119 | CLEANSING AGENT | Non-Final OA | Shiseido Company, Ltd. |
| 17310238 | SUNSCREEN COMPOSITIONS | Non-Final OA | BEIERSDORF AG |
| 18869925 | MOLECULARLY CLEAVABLE BIOINK FORMULATION | Non-Final OA | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. |
| 18023274 | SOL-GEL COMPOSITION | Non-Final OA | THE UNIVERSITY OF QUEENSLAND |
| 18246582 | GASTRO RETENTIVE DOSAGE FORMS COMPRISING DEUTETRABENAZINE | Final Rejection | AUSPEX PHARMACEUTICALS, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy